Motor neurone disease (MND): investigational drug treatments
Evidence-based neurology checklist on motor neurone disease (mnd): investigational drug treatments: Repurposed treatments Anakinra Biotin (MD1003) Fingolimod Ibudilast Melatonin Rasagiline Stem cell therapy Tamoxifen Other investigational treatments Failed investigational treatments
Repurposed treatments
- Anakinra
- Biotin (MD1003)
- Fingolimod
- Ibudilast
- Melatonin
- Rasagiline
- Stem cell therapy
- Tamoxifen
Other investigational treatments
Failed investigational treatments
References
- Khalid SI, Ampie L, Kelly R, Ladha SS, Dardis C. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front Neurol 2017; 8:486.
- Juntas-Morales R, Pageot N, Bendarraz A, et al. High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: a pilot study. EClinicalMedicine 2020; 19:100254.
- Berry JD, Paganoni S, Atassi N, et al. Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability. Muscle Nerve 2017; 56:1077-1084.
- Bald EM, Nance CS, Schultz JL. Melatonin may slow disease progression in amyotrophic lateral sclerosis: findings from the Pooled Resource Open-Access ALS Clinic Trials database. Muscle Nerve 2021 (Online ahead of print).
- Ludolph AC, Schuster J, Dorst J, et al; RAS-ALS Study Group. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurol 2018; 17:681-688.
- And 14 more. Subscribe to see the full list
